Previous 10 | Next 10 |
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ) for cancer, today announced that the U.S...
2023-06-17 23:06:34 ET Summary Merus has shown positive developments in clinical trials and regulatory meetings with the FDA, resulting in increased collaboration revenue and a more constructive investment outlook. Despite these positive factors, the company's current valuation of...
2023-06-15 07:56:47 ET Oncology company Merus ( NASDAQ: MRUS ) appointed Greg Perry CFO on June 14. Perry has also been designated as the company's principal financial officer, succeeding Bill Lundberg. Perry has served as a non-executive director of th...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced the appointment of Greg ...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg, M.D....
2023-05-04 17:54:55 ET Merus press release ( NASDAQ: MRUS ): Q1 GAAP EPS of -$0.86 beats by $0.17 . Revenue of $13.5M (+15.8% Y/Y) beats by $2.21M . For further details see: Merus GAAP EPS of -$0.86 beats by $0.17, revenue of $13.5M beats by $2.21M
– Petosemtamab clinical update presented at the American Association of Cancer Research (AACR) Annual Meeting 2023 – Petosemtamab end-of-phase meeting with U.S. Food & Drug Administration provides clarity to potential registration path in head and neck squamous cell carcin...
2023-04-17 12:55:02 ET Dutch biotech Merus ( NASDAQ: MRUS ) gained ~13% on Monday after announcing interim data for its bispecific antibody petosemtamab from a Phase 1/2 trial in previously treated head and neck squamous cell carcinoma (HNSCC). Citing a presentation at the o...
- 37% overall response rate (ORR) observed in 43 evaluable patients - 6 months median duration of response as of Feb. 1, 2023 data cutoff date - End-of-phase meeting with U.S. Food & Drug Administration provides clarity to potential registration path in HNSCC - Investor call on April 17...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced t...
News, Short Squeeze, Breakout and More Instantly...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...
2024-07-13 04:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...